ScripsAmerica Inc. (SCRCQ)

[coolerheadsprevail]

why don´t they change from otc to nasdaq. the pps will be go up

@sandschnur,

I think I get the gist of what you are INTENDING to say, but from a procedural perspective, your "cause and effect" is technically backwards.

Yes, the sp will go up, but it is only because in order to uplist, the sp must first meet the minimum sp threshold as mandated by the listing requirements of the exchange SCRC may wish to uplist onto.

And in order to meet this minimum sp threshold, one of two things needs to happen:

(1)
SCRC needs to magically report $25M per month in approved orders for Main Ave beginning NOW, as this 5-fold increase should jumpstart the sp by sending the market into an unprecedented buying frenzy...

(2)
SCRC needs to effectuate a R/S.


So you can see that it is rather obvious that scenario (2), the R/S, is the most likely scenario.

BS Schneiderman went on record at the SeeThruEquity microcap investor conference last NOV'14 as saying that he intends to uplist SCRC onto a senior exchange in 2015.

Well, FEB is almost at an end, and as I have been saying for months now, if BS Schneiderman is serious about uplisting -- and is NOT simply the latest of an endless stream of penny stock CEO's who all thump their chests and claim they intend to uplist BUT NEVER DO IT -- then he needs to put his money where his mouth is and get the wheels turning on effectuating the R/S NOW. In fact, BS Schneiderman should have began conducting the proxy months ago.

Uplisting takes time and effectuating a R/S (which is the FIRST thing that needs to happen) takes time as well, as it requires preparing and sending out proxy materials, allowing adequate time for votes to be submitted, then formal tabulation.

And, yes, this effort takes money. Which SCRC has. And by spending this modest sum to actually initiate the proxy vote on a R/S, SCRC is sending a BOOMING UBER-BULLISH signal to the Street (which can be very beneficial for shareholders) that it is SERIOUS about uplisting. How? Because 99% of penny stock CEO's who claim to want to uplist never put their money where their mouth is and never even take this initial step to effectuate a R/S. By spending the money to conduct a proxy, SCRC is loudly separating itself from the 99% of other penny stocks who never have any real intention of uplisting in spite of their public touts of wanting to do so.

And, remember, all this proxy is doing is granting SCRC the authority to effectuate a R/S. That's it. The proxy does not have to specify a time window (although it could) and the proxy does not have to specify a R/S ratio (for example, it can simply state "to authorize a R/S of between 1:2 to 1:100"). This way, in addition to sending a bullish signal to the market, SCRC positions itself to be ready to effectuate the R/S on a moment's notice when it is ready to go thru the formal uplisting protocol.

There is NOTHING TO LOSE but EVERYTHING TO GAIN by conducting the proxy to authorize a R/S immediately. The longer BS Schneiderman waits, the more the Street will perceive his claims as nothing more than the next in an already long list of undelivered forward looking statements from him. And it is this scarlet letter that comes with constantly over-promising and under-delivering that has been punishing shareholders for years now.

Hopefully, Gregory FCA will put an end to this bad habit that BS Schneiderman apparently is unable to shake off...


**********************

Alleyba had a vision that starting in March we will be over $4m plus again. Alleyba's vision was blurred at end but he saw record setting numbers for PIMD because of the diabetic business

@Alleyba,

(1)
Is this what it has come to? What is it with these never-ending deceptive statements hyping PIMD to high heaven?

First, it was "SCRC will be able to ring the bell twice and double-dip on revenues when PIMD sells to Main Ave!"...

...and now it is "PIMD will see record-setting revenues because of the diabetic business!"...

...ummm, hate to break the news to you, but PIMD has no diabetic business. The diabetic equip/supply segment is part of Main Ave...

...in addition, considering that only $137k was reported for JAN, it certainly shouldn't take much to "set a new record" -- and until any new "record" begins to creep into the $250k-$500k per month range, it will be immaterial to SCRC as a consolidated entity and is as un-news-worthy as the monthly WRx numbers, which are 100% pure profit, but only amount to approx $15k/month to the bottom line. Let's keep things real. The ONLY segment of shareholders who benefit from baseless hype are the holders of discounted stock (specifically, JOSEPH ZAMPETTI and his "inner circle" (LOL!) of fellow Section 17(b)-violating criminals who were given 28M shares of 0.00 and toxic 0.05 PIPE stock) who are looking to unload them onto unsuspecting sheeple...

...and keep in mind that BS Schneiderman NEVER disclosed how much of the $137k in PIMD revenues last month (if any) may have pertained to sales to Main Ave -- because, as explained numerous times already, any such sales between related parties get eliminated and DO NOT COUNT under US GAAP.

(2)
A "vision"??? Is this what qualifies as DD nowadays?


********************

Compound Pharmacy is not facing anything unusual right now. My 37 years in the industry allows me to say with confidence all pharma companies deal with the same deductible issue patients face at the beginning of the year.

@Guts,

Sorry, but real-world numbers simply don't support your statements.

Deductibles certainly can impact Q1 numbers of bio/pharma businesses, but it would not come close to single-handedly explaining the massive 35% drop in JAN'15 numbers compared to last NOV & DEC (and please don't try to bring up the closures again because we have already gone thru the math and proven that the number of business days in JAN is comparable to NOV even after factoring in all the extra closure dates in JAN).

By way of comparison, just look at the Q1 variances experienced by Eli Lilly and Amgen, two major public pharma companies who each have tons of drugs on the market that everyday folks obtain Rx's for and get filled from their local pharmacies.

For Eli Lilly, the Q1 variance in revenues from Q2 was only a drop of 5.1% in 2013 and only 4.1% in 2014.

For Amgen, the Q1 variance in revenues from Q2 was only a drop of 8.7% in 2013 and only 10.2% in 2014.

Again, certainly a drop in Q1 relative to Q2, but only either modest or moderate -- NOTHING close to the 35% drop experienced by Main Ave.

I stand by my prior statements that there was something else in play that weighed down on Main Ave's JAN numbers beyond simply the closures and the deductibles being reset...